Arcus Biosciences (RCUS) Free Cash Flow Growth (3y) (2020 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 24.91% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 20.11% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 14.71% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -10.65% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 31.42% |
| 10 | Arcus Biosciences | 3.18 Bn | 2.36 Bn | - | -10.96% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.96% |
| Dec 31, 2025 | -19.35% |
| Sep 30, 2025 | -5.33% |
| Jun 30, 2025 | -25.06% |
| Mar 31, 2025 | -30.13% |
| Dec 31, 2024 | -30.58% |
| Sep 30, 2024 | 33.62% |
| Jun 30, 2024 | -7.68% |
| Mar 31, 2024 | 64.85% |
| Dec 31, 2023 | -10.89% |
| Sep 30, 2023 | -32.72% |
| Jun 30, 2023 | -37.52% |
| Mar 31, 2023 | -47.48% |
| Dec 31, 2022 | -94.93% |
| Sep 30, 2022 | -46.77% |
| Jun 30, 2022 | -49.01% |
| Mar 31, 2022 | 241.78% |
| Dec 31, 2021 | -61.61% |
| Sep 30, 2021 | -81.41% |
| Jun 30, 2021 | -90.78% |
| Mar 31, 2021 | -70.50% |
| Dec 31, 2020 | -93.37% |
| Sep 30, 2020 | 123.04% |
| Jun 30, 2020 | -56.58% |
| Mar 31, 2020 | -43.31% |